Cargando…

A stated preference survey to explore patient preferences for novel preventive migraine treatments

OBJECTIVE: The objective of this study was to explore patient preference for attributes of calcitonin gene‐related peptide (CGRP) inhibitors for the preventive treatment of migraine and to describe differences in treatment preferences between patients. BACKGROUND: CGRP inhibitors are a novel class o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hubig, Lena T., Smith, Timothy, Chua, Gin Nie, Lloyd, Andrew J., Powell, Lauren, Johnston, Karissa, Harris, Linda, L'Italien, Gilbert, Coric, Vladimir, Lo, Siu Hing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Submissions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826196/ https://www.ncbi.nlm.nih.gov/pubmed/36047857 http://dx.doi.org/10.1111/head.14386

Ejemplares similares

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021)

Measuring interictal burden among people affected by migraine: a descriptive survey study
por: Hubig, Lena T., et al.
Publicado: (2022)

Real-World experience of interictal burden and treatment in migraine: a qualitative interview study
por: Lo, Siu Hing, et al.
Publicado: (2022)

Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States
por: Harris, Linda, et al.
Publicado: (2022)

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
por: Johnston, Karissa M, et al.
Publicado: (2022)

Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
por: Johnston, Karissa, et al.
Publicado: (2022)

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
por: Johnston, Karissa M., et al.
Publicado: (2021)

Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)
por: Powell, Lauren C., et al.
Publicado: (2022)

Patient preference for early onset of efficacy of preventive migraine treatments
por: Ailani, Jessica, et al.
Publicado: (2022)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial
por: Croop, Robert, et al.
Publicado: (2022)

The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review
por: Deighton, Alison M., et al.
Publicado: (2021)

Observational Analysis of the Costs Associated with Acute Treatment of Breakthrough Migraine Attacks in Medicaid Patients Using Preventive Therapies
por: Harris, Linda, et al.
Publicado: (2023)

Subjective sensory sensitivity and its relationship with anxiety in people with probable migraine
por: Price, Alice, et al.
Publicado: (2021)

Management of migraine headaches in a chronic pain patient: A case report
por: Bach, Linda Lu, et al.
Publicado: (2016)

Development and validation of a novel patient‐reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary
por: Lipton, Richard B., et al.
Publicado: (2021)

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine
por: Ford, Janet H., et al.
Publicado: (2020)

Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale
por: Lipton, Richard B., et al.
Publicado: (2017)

Characterization of Familial and Sporadic Migraine
por: Ravn, Julie, et al.
Publicado: (2019)

Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study
por: Munjal, Sagar, et al.
Publicado: (2019)

A Qualitative Study to Assess the Content Validity of the 24‐Hour Migraine Quality of Life Questionnaire in Patients with Migraine
por: Speck, Rebecca M., et al.
Publicado: (2020)

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Buse, Dawn C., et al.
Publicado: (2019)

Comparison and predictors of chronic migraine vs. new daily persistent headache presenting with a chronic migraine phenotype
por: Nagaraj, Karthik, et al.
Publicado: (2022)

United States Patients’ Perspective of Living With Migraine: Country‐Specific Results From the Global “My Migraine Voice” Survey
por: Gibbs, Sarah N., et al.
Publicado: (2020)

The migraine signature study: Methods and baseline results
por: Pressman, Alice R., et al.
Publicado: (2020)

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Dodick, David W., et al.
Publicado: (2016)

Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes – The Migraine Functional Impact Questionnaire (MFIQ)
por: Hareendran, Asha, et al.
Publicado: (2018)

The Effect of Psychiatric Comorbidities on Headache‐Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Lipton, Richard B., et al.
Publicado: (2020)

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
por: Lipton, Richard B., et al.
Publicado: (2020)

Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials
por: Stauffer, Virginia L., et al.
Publicado: (2019)

Alcohol as a trigger of migraine attacks in people with migraine. Results from a large prospective cohort study in English‐speaking countries
por: Vives‐Mestres, Marina, et al.
Publicado: (2022)

Migraine Genetic Variants Influence Cerebral Blood Flow
por: Knol, Maria J., et al.
Publicado: (2019)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Trial
por: Yarnitsky, David, et al.
Publicado: (2019)

A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache‐Related Disability
por: Lipton, Richard B., et al.
Publicado: (2016)

Evidence that blood–CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen
por: Cowan, Robert P., et al.
Publicado: (2021)

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
por: Marmura, Michael J., et al.
Publicado: (2021)

Evaluating the Psychometric Properties of the Migraine Functional Impact Questionnaire (MFIQ)
por: Kawata, Ariane K., et al.
Publicado: (2019)

Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
por: Rothrock, John F, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_phbeohbslo3l8mpi63srqtk728